HC Wainwright Reaffirms “Buy” Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reissued their buy rating on shares of Agenus (NASDAQ:AGEN) in a research note issued to investors on Friday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the company. B. Riley lowered their price target on Agenus from $120.00 to $100.00 and set a buy rating on the stock in a research report on Monday, March 18th. StockNews.com began coverage on Agenus in a research report on Wednesday, April 17th. They issued a hold rating on the stock.

Agenus Stock Down 0.4 %

Shares of NASDAQ AGEN opened at $16.69 on Friday. The business’s 50 day moving average price is $13.45 and its two-hundred day moving average price is $12.94. The company has a market cap of $350.49 million, a PE ratio of -1.30 and a beta of 1.32. Agenus has a twelve month low of $4.78 and a twelve month high of $38.60.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.54. The business had revenue of $28.01 million for the quarter, compared to analyst estimates of $40.70 million. As a group, research analysts anticipate that Agenus will post -9.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several institutional investors and hedge funds have recently made changes to their positions in AGEN. Vanguard Group Inc. grew its position in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Agenus by 3,008.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock valued at $1,909,000 after buying an additional 2,232,064 shares during the period. Braidwell LP boosted its stake in shares of Agenus by 34.3% in the third quarter. Braidwell LP now owns 6,307,030 shares of the biotechnology company’s stock valued at $7,127,000 after buying an additional 1,609,100 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Agenus by 1,959.9% in the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 720,629 shares during the period. Finally, Pennant Investors LP bought a new stake in shares of Agenus in the fourth quarter valued at approximately $389,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.